Cardiac antiplatelet therapy stands as a cornerstone in the realm of cardiovascular health management, contributing significantly to the prevention of blood clot formation—a key factor in various heart-related issues. This therapeutic approach involves the administration of medications designed to impede platelet activity, thereby mitigating the risk of blood vessel blockages and potential cardiovascular events. Beyond the widely recognized use of aspirin as a prominent antiplatelet agent, newer medications like ticagrelor and prasugrel have emerged, providing additional options for individuals with specific cardiovascular conditions. The nuanced application of antiplatelet therapy is intricately tailored to each patient's distinct medical profile, ensuring a precise and effective strategy for preserving heart health. In an era marked by continual advancements in cardiovascular medicine, the significance of cardiac antiplatelet therapy persists as a crucial element in the ongoing pursuit of comprehensive and individualized cardiovascular care.
Title : Revolutionizing CKD care: How finerenone transforms outcomes in heart and kidney health - Insights from fidelio-DKD
Robert J Chilton, University of Texas Health Science Center San Antonio, United States
Title : Novel important cellular responses, signaling mechanisms and therapeutic options for pulmonary hypertension and right heart failure
Yong Xiao Wang, Albany Medical Center, United States
Title : Preventing sports-related cardiac arrest: Coronary artery calcium scoring stratifies the benefit of low-dose aspirin use for risk reduction
Arthur J Siegel, Massachusetts General Hospital, United States
Title : Empathy and precision: Revolutionizing communication between cardiologists and patients
Iris Panagiota Efthymiou, University of Greenwich, United Kingdom
Title : Post-cardiotomy ECMO (PC-ECMO)
Gustavo Lionel Knop, Mayo Clinic, United States
Title : The past, present and future of AI in cardiology
Narendra Kumar, HeartbeatsZ Academy, United Kingdom